These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38055218)

  • 1. Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses.
    Qiu J; Zhang S; Feng Y; Su X; Cai J; Chen S; Liu J; Huang S; Huang H; Zhu S; Wen H; Li J; Yan H; Diao Z; Liang X; Zeng F
    Expert Rev Vaccines; 2024; 23(1):69-81. PubMed ID: 38055218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009].
    Yan B; Lyu J; Liu J; Feng Y; Xu A; Chen S; Zhou L; Liang X; Cui F; Wang F; Zhang L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Dec; 48(12):1043-7. PubMed ID: 25619213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Girndt M; Houser P; Manllo-Karim R; Ervin JE; Charytan C; Chow S; Symonian-Silver M; Lehrner L; Linfert D; Shemin D; Michelsen A; Xie F; Janssen RS
    Vaccine; 2023 May; 41(20):3224-3232. PubMed ID: 37085451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections.
    Song Y; Zhang X; Liu M; Zhai X; Liu J; Li Y; Li L; Xiao Y; Duan Z; Jiang J; Ding F; Zhu L; Jiang J; Zou H; Zhuang H; Wang J; Li J
    BMC Infect Dis; 2022 Nov; 22(1):863. PubMed ID: 36401190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of early horizontal transmission of hepatitis B virus in children of uninfected mothers in sub-Saharan Africa: a systematic review and meta-analysis.
    Ansari A; Vincent JP; Moorhouse L; Shimakawa Y; Nayagam S
    Lancet Glob Health; 2023 May; 11(5):e715-e728. PubMed ID: 37061310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China.
    Miao N; Zheng H; Sun X; Zhang G; Wang F
    Sci Rep; 2020 Oct; 10(1):18155. PubMed ID: 33097788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
    Girndt M; Plüer M; Dellanna F; Michelsen AK; Beige J; Toussaint K; Wehweck HJ; Koch M; Hafezi Rachti S; Faust J; Bosselmann HP; Witzke O; Janssen RS;
    Hum Vaccin Immunother; 2022 Nov; 18(6):2136912. PubMed ID: 36269938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus infection seromarkers among college freshmen and their immune responses to different vaccination policies of hepatitis B vaccine.
    Xu Y; Liu Y; Wang J; Che X; Zhang X; Jiang W; Du J; Zhang X; Gu W
    Hum Vaccin Immunother; 2021 Nov; 17(11):4587-4594. PubMed ID: 34407383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
    Manley HJ; Aweh G; Frament J; Ladik V; Lacson EK
    Nephrol Dial Transplant; 2023 Feb; 38(2):447-454. PubMed ID: 35150277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.
    Marks KM; Kang M; Umbleja T; Avihingsanon A; Sugandhavesa P; Cox AL; Vigil K; Perazzo H; Price JC; Katsidzira L; Vernon C; Alston-Smith B; Sherman KE;
    Clin Infect Dis; 2023 Aug; 77(3):414-418. PubMed ID: 37017075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.
    Champion CR
    Ann Pharmacother; 2021 Jun; 55(6):783-791. PubMed ID: 32988213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Zubkova I; Zhao Y; Cui Q; Kachko A; Gimie Y; Chabot S; Murphy T; Schillie S; Major M
    Vaccine; 2023 Jan; 41(4):955-964. PubMed ID: 36586740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China.
    Yu W; Liu D; Zheng J; Liu Y; An Z; Rodewald L; Zhang G; Su Q; Li K; Xu D; Wang F; Yuan P; Xia W; Ning G; Zheng H; Chu Y; Cui J; Duan M; Hao L; Zhou Y; Wu Z; Zhang X; Cui F; Li L; Wang H
    Int J Epidemiol; 2016 Apr; 45(2):441-9. PubMed ID: 27174834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing hepatitis B virus infection among healthcare professionals: potential impact of a 2-dose versus 3-dose vaccine.
    Stevenson C; Youn JH; Hayney MS; David C
    Hum Vaccin Immunother; 2021 Nov; 17(11):4567-4577. PubMed ID: 34505827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The epidemiological characteristics of HBV susceptibility in 1-29 years old young people in China in 2006 and 2014: based on the national sero-survey data analysis].
    Zheng H; Wang FZ; Zhang GM; Miao N; Sun XJ; Cui FQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):581-586. PubMed ID: 28693080
    [No Abstract]   [Full Text] [Related]  

  • 16. Low Level of Hepatitis B Virus Infection in Children 20 Years After Initiation of Infant Vaccination Program in Wallis and Futuna.
    Pezzoli L; Mathelin JP; Hennessey K; Eswara-Aratchige P; Valiakolleri J; Kim SH
    Am J Trop Med Hyg; 2017 Mar; 96(3):715-719. PubMed ID: 28070010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study].
    Lyu JJ; Zhang L; Yan BY; Liu JY; Feng Y; Song LZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):478-83. PubMed ID: 27256725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of booster dose vaccination 21- to 32-years after primary vaccination with hepatitis B vaccine in the population born from 1986 to 1996 in Zhengding County of Hebei Province].
    Zhang XJ; Wu ZW; Zhang YH; Li MJ; Zhou HS; Han BH; Hao ZY; Chu J; Gao Z; Ma JC; Zhao YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):942-946. PubMed ID: 32907282
    [No Abstract]   [Full Text] [Related]  

  • 19. Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
    Janssen RS; Bruxvoort K; Jacobsen SJ; Slezak J; David C; Hyer R; Poland GA
    Vaccine; 2021 Sep; 39(39):5666-5672. PubMed ID: 34404556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017.
    Khetsuriani N; Zaika O; Chitadze N; Slobodianyk L; Allahverdiyeva V; O'Connor P; Huseynov S
    Vaccine; 2021 Mar; 39(10):1485-1492. PubMed ID: 33583671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.